相关实验视频
Updated: Jul 19, 2025

07:50
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
5.6K
与DNA甲基化相关的lncRNAs预测胃癌的预后和免疫治疗反应
Xiong Guo1, Yujun Wang2, Lang Zha1
1Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Journal of cancer research and clinical oncology
|August 17, 2023
概括
研究人员开发了一种使用长非编码RNA (lncRNA) 和DNA甲基化来预测胃癌 (GC) 患者结果的新模型. 较低的lncRNA得分表明更好的预后和免疫治疗反应,有助于治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 长非编码RNAs (lncRNAs) 和DNA甲基化对于癌症的发展和免疫反应至关重要.
- lncRNAs,DNA甲基化之间的相互作用,以及它们在胃癌 (GC) 中的临床意义尚未得到充分理解.
研究的目的:
- 在胃癌中识别与DNA甲基化调节器相关的lncRNAs.
- 建立一个预后模型,用于预测GC中的患者存活率和治疗反应.
- 探索 lncRNA 表达模式与瘤免疫微环境之间的关系.
主要方法:
- 利用癌症基因组图谱 (TCGA) 数据集进行lncRNA和DNA甲基化分析.
- 采用皮尔森相关性,单变Cox回归和最小绝对收缩和选择运算子 (LASSO) Cox回归来构建预后模型.
- 为患者分层和生存预测开发了名图和lncRNA得分.
主要成果:
- 建立了一个基于13个lncRNA的预后模型,准确预测GC患者的存活率.
- 较高的lncRNA得分与更糟糕的预后相关,减少瘤突变负担和免疫抑制.
- 较低的lncRNA得分与增加的新抗原负载,增强的抗PD-1/CTLA-4免疫疗法反应和更好的临床益处有关.
结论:
- 一种与DNA甲基化调节器相关的新型lncRNA签名模型为预测治疗反应和分层胃癌患者提供了一种新方法.
- 评估lncRNA表达模式可以提高对瘤微环境的理解,并指导个性化免疫疗法策略.
相关概念视频
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Epigenetic Regulation
3.1K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.1K
Non-LTR Retrotransposons
11.6K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K

